General description
5-Fluoroisatin has been reported as the precursor of the Sunitinib (Sutent) drug. 5-Fluoroisatin has been approved by the Food and Drugs Administration (FDA) in 2006 for the treatment of renal cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST).
Application
5-Fluoroisatin may be used:
- as reaction-based probe for live-cell detection of peroxynitrite by 19F magnetic resonance spectroscopy
- in non-invasive detection of peroxynitrite (ONOO(-)) formation in living lung epithelial cells stimulated with interferon-γ (IFN-γ)
- in the synthesis of bis-Schiff bases, via condensation with aromatic primary bis-amines in water suspension medium without using any organic solvent or acid catalyst
- in the synthesis of 3-acetonyl-5-fluoro-3-hydroxyoxindole
Reactant for preparation of:
- Spiro[indole-thiazolidinones] as biologically relevan synthesis scaffolds
- Potential antimycobacterial agents
- Inhibitors of c-Met kinase
- Inhibitors of TAK1 kinase
- Herpes simplex virus inhibitors
- IKKβ inhibitors
- Inhibitors of vitiligo disease
- Potential drug candidates with anti-HIV activity and anti-tubercular activity
- UPC:
- 51111875
- Condition:
- New
- Availability:
- 3-5 Days
- Weight:
- 1.00 Ounces
- HazmatClass:
- No
- MPN:
- 366978-5G
- CAS:
- 443-69-6
